SCIENCE: An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels

Speech sensitive to treatment response

 

Click here for more details.

Tags: , , ,

Related Post

Redenlab announces landmark study in collaboration with Queensland Institute of Medical Research

  • Posted on 11 December, 2024
    MEDIA RELEASE Melbourne - December 2024 – Redenlab, a leader in innovative healthcare solutions, has partnered with the Queensland Institute of Medical...
    Read more

    Expanding the phenotype of Kleefstra syndrome: speech, language and cognition in 103 individuals

    • Posted on 31 March, 2024
      Speech and language impairments are core features of the neurodevelopmental genetic condition Kleefstra syndrome. The speech, language and cognitive profile...
      Read more

      Redenlab’s Chief Science Officer, Adam P. Vogel, PhD, leads groundbreaking study on speech analysis for neurodegenerative diseases

      • Posted on 25 January, 2024
        MEDIA RELEASE Melbourne, 19 January 2024 — Redenlab, a leader in innovative healthcare solutions, ispleased to announce a groundbreaking study...
        Read more